Investigating the Relationship between Using Natalizumab in Patients with Multiple Sclerosis on Developing Depression

Abstract

Aims: This study aimed to investigate the relationship between using Natalizumab in patients with Multiple Sclerosis on developing Depression. Method: The Beck Depression Inventory (BDI-II) was used in this quasi-experimental study of 54 Multiple Sclerosis patients receiving Natalizumab. The mean of Depression before using the Natalizumab was 28.94, which is in the range of 16-31; the patients had mild Depression, but after using the Natalizumab, the mean of Depression was 48.38, which showed deep Depression. So, the mean of Depression in the post-test was more than the pre-test. Results: The Natalizumab's effect after one month of using Natalizumab was slightly more significant than before using Natalizumab. Obtained data indicated that patients had no significant depressive symptoms before treatment and before using Natalizumab, but after treatment with Natalizumab, depressive symptoms increased. Conclusion: Multiple sclerosis patients may experience Depression after receiving Natalizumab.